Lessons Learned from Pharmaceutical Nanomaterials - Safety of Nanomaterials along Their Lifecycle - page 129

the huge data sets. In a best case scenario all the subdisciplines coevolve and assist
each other. The way we perform current studies, even when not intended for use in
humans, should follow current best methods and protocols in particle characteriza-
tion and toxicity testing. Only then the data we create are of use in data collections,
which can be the starting point of the risk prediction. Larger cooperation projects
and academia-industry cooperation are important to take the lead in organization and
management of such data collections.
There is no need to exaggerate—neither potentially achievable advantages nor
possible risk. A realistic appraisal of both sides is the order of the day. Fatal errors
with too fast marketing of nanotechnology-based products have to be avoided as
they can complicate or even stop the development process and marketing chances of
many other products by nonrational reasons. For nanopharmaceuticals, however, we
have very stringent regulatory systems in place evaluating not only before regulatory
approval but also monitoring in clinical use.
REFERENCES
Adler-Moore, J. P. and R. T. Proffitt (1993) Development, characterization, efficacy and
mode of action of ambisome, a unilamellar liposomal formulation of Amphotericin B.
J Liposome Res 3 (3):429-450.
Agency, European Medicines (2004) EMED formulation (Scientific Discussion). 35.
Aggarwal, P., J. B. Hall, C. B. McLeland, M. A. Dobrovolskaia, and S. E. McNeil (2009)
Nanoparticle interaction with plasma proteins as it relates to particle biodistribution,
biocompatibility and therapeutic efficacy. Adv Drug Deliv Rev 61 (6):428-437.
Almeida, A. J. and E. Souto (2007) Solid lipid nanoparticles as a drug delivery system for
peptides and proteins. Adv Drug Deliv Rev 59 (6):478-90.
Bailey, C. J. and A. H. Barnett (2007) Why is Exubera being withdrawn? BMJ 335
(7630):1156-1156.
Bawa, R. (2008) Nanoparticle-based therapeutics in humans: A survey. Nanotechnol Law
Business 5 (2):135-155.
Bawa, R. (2009) Nanopharmaceuticals for drug delivery—A review. Touch Briefings
6:122-127.
Bekersky, I., R. M. Fielding, D. E. Dressler, J. W. Lee, D. N. Buell, and T. J. Walsh
(2002) Pharmacokinetics, excretion, and mass balance of liposomal amphoteri-
cin B (AmBisome) and amphotericin B deoxycholate in humans. Antimicrob Agents
Chemother 46 (3):828-833.
Berne, B. and R. Pecora (1976) Dynamic light scattering with application to chemistry, biol-
ogy and physics . J. Wiley & Sons: New York.
Birrenbach, G., P. Speiser (1977) Microcapsules in the nanometric range and a method for
their production. US-Patent 4,021,364.
Bondy, S. C (2011) Nanoparticles and colloids as contributing factors in neurodegenerative
disease. Int J Environ Res Public Health 8 (6):2200-2211.
Boswell, G. W., I. Bekersky, D. Buell, R. Hiles, and T. J. Walsh (1998) Toxicological profile
and pharmacokinetics of a unilamellar liposomal vesicle formulation of amphotericin B
in rats. Antimicrob Agents Chemother 42 (2):263-268.
Brannen, K. C., J. M. Panzica-Kelly, T. L. Danberry, and K. A. Augustine-Rauch (2010)
Development of a zebrafish embryo teratogenicity assay and quantitative prediction
model. Birth Defects Res B Dev Reprod Toxicol 89 (1):66-77.
Brittain, H. G. (2001) X-ray diffraction III: Pharmaceutical applications of x-ray powder
diffraction. Spectroscopy 16 (7):14-18.